...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta oncologica. >A phase II study of hypofractionated proton therapy for prostate cancer
【24h】

A phase II study of hypofractionated proton therapy for prostate cancer

机译：前列腺癌超分割质子治疗的II期研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. Hypofractionated radiotherapy potentially offers therapeutic gain for prostate cancer. We investigated the feasibility of hypofractionated proton therapy (PT). Material and methods. Eighty-two patients with biopsy-proven T1-3N0M0 prostate adenocarcinoma and no history of androgen deprivation therapy were randomly assigned to five different dose schedules: Arm 1, 60 CGE (cobalt gray equivalent = proton dose in Gy × 1.1)/20 fractions/5 weeks; Arm 2, 54 CGE/15 fractions/5 weeks; Arm 3, 47 CGE/10 fractions/5 weeks; Arm 4, 35 CGE/5 fractions/2.5 weeks; or Arm 5, 35 CGE/5 fractions/5 weeks. Results. The median follow-up duration was 42 months (11-52 months). The acute GI and GU grade ≥ 2 toxicity rates were 0 and 5%, respectively. The late GI and GU grade ≥ 2 toxicity rates were 16% and 7%, respectively. The best arm for acute GU toxicity was Arm 3, while that for late GI toxicity was Arm 2 in which none had grade ≥ 2 toxicity. The four-year American Society for Therapeutic Radiology and Oncology and Nadir + 2ng/ml BCF free survival (BCFFS) rates were 85% and 86%, respectively. Conclusions. Hypofractionated PT for patients with prostate adenocarcinoma as used in this study is feasible with an acceptable toxicity profile. As the BCFFS rates do not seem to be inferior to those produced using conventional fractionation, the application of hypofractionated PT may save patients time and money.
机译：背景。超分割放射疗法可能为前列腺癌提供治疗益处。我们研究了低级质子治疗（PT）的可行性。材料与方法。将82例经活检证实为T1-3N0M0前列腺腺癌且无雄激素剥夺治疗史的患者随机分配到五种不同的剂量方案：第1组，60 CGE（钴灰色当量=质子剂量，Gy×1.1）/ 20分数/ 5周;第二组，54 CGE / 15分数/ 5周;第三组，47 CGE / 10分数/ 5周;第4组，35 CGE / 5分数/2.5周;或第5组，35 CGE / 5分数/ 5周。结果。中位随访时间为42个月（11-52个月）。 ≥2的急性GI和GU的毒性率分别为0和5％。 GI和GU≥2级的晚期毒性率分别为16％和7％。急性GU毒性的最佳组别是Arm 3，而GI晚期毒性的最佳组别是Arm 2，其中没有2级以上的毒性。四年的美国放射治疗与肿瘤学会和Nadir + 2ng / ml BCF存活率（BCFFS）分别为85％和86％。结论本研究中使用的前列腺癌患者的超分割PT是可行的，并且具有可接受的毒性。由于BCFFS速率似乎并不比使用常规分级分离产生的速率低，因此应用次分级PT可以节省患者的时间和金钱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号